financetom
Business
financetom
/
Business
/
Top Google and Facebook executives onboarded by Indian ad regulator
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Top Google and Facebook executives onboarded by Indian ad regulator
Aug 27, 2021 9:16 AM

India’s advertising regulator, the Advertising Standards Council of India (ASCI), has onboarded Aditya Swamy, Director of Google India. Sandeep Bhushan, Head of India Global Marketing Solutions at Facebook, has also joined the board as a special invitee.

The 36-year-old ASCI also announced the launch of a new logo and said its focus would be on digital advertising. To be ahead of the curve in the digital space, it has streamlined guidelines for digital advertising and formulated rules to monitor advertisements on various social media platforms also.

The onboarding of Aditya Swamy and Sandeep Bhushan will help the Indian regulator to formulate better policies and guidelines for the industry.

Subhash Kamath, Chairman, ASCI, said it is extremely important that ASCI collaborates with and learn from the leaders. Google and Facebook are the biggest digital players he added.

According to a recent report by Dentsu, digital ad spends in India grew by 20 percent in 2019 to 29.4 percent in 2021 while television grew by 7.7 percent in the same period. Television was the preferred and most-used advertising medium.

The report also said the digital market share of 35 percent has overtaken print media, which has a 16 percent market share, and is fast approaching the television medium, which has a lion’s share of 45 percent, as per the 2021 estimates by media agency GroupM.

The digital medium grew quicker and continues to expand due to availability of cheap data and smartphones along with the pandemic that ensured extended lockdowns was the norm.

(Edited by : Shoma Bhattacharjee)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Core Scientific Rejects CoreWeave's Acquisition Offer
Core Scientific Rejects CoreWeave's Acquisition Offer
Jun 6, 2024
08:44 AM EDT, 06/06/2024 (MT Newswires) -- Core Scientific ( CORZ ) said on Thursday it had rejected CoreWeave's proposal to buy all of its outstanding shares for $5.75 per share in cash, as it significantly undervalues the company and is not in the best interests of the shareholders. The company said it received the unsolicited proposal from CoreWeave on...
Sector Update: Consumer
Sector Update: Consumer
Jun 6, 2024
08:44 AM EDT, 06/06/2024 (MT Newswires) -- Consumer stocks were leaning lower pre-bell Thursday as the Consumer Staples Select Sector SPDR Fund (XLP) was down 0.1% and the Consumer Discretionary Select Sector SPDR Fund (XLY) was marginally declining recently. Five Below ( FIVE ) declined by over 18% as its fiscal Q1 sales and earnings lagged market expectations and the...
Bitdeer Technologies Group Agrees to Acquire Desiweminer in All-Stock Deal
Bitdeer Technologies Group Agrees to Acquire Desiweminer in All-Stock Deal
Jun 6, 2024
08:43 AM EDT, 06/06/2024 (MT Newswires) -- Bitdeer Technologies Group ( BTDR ) said Thursday that it has agreed to acquire all issued and outstanding shares of Desiweminer for 20 million Class A ordinary shares. Bitdeer ( BTDR ) said a portion of the shares to be issued will vest in equal installments over five or seven years. Additionally, Bitdeer...
HEALWELL AI Unit Partners With Takeda for Rare Disease Evidence Analysis
HEALWELL AI Unit Partners With Takeda for Rare Disease Evidence Analysis
Jun 6, 2024
08:45 AM EDT, 06/06/2024 (MT Newswires) -- HEALWELL AI (AIDX.TO) unit Pentavere Research Group partnered with Takeda Canada to pursue real-world evidence analysis for rare diseases. The partnership will focus on supporting patients suffering from hereditary angioedema (HAE) with normal C1 inhibitor across Canada. HAE with normal C1 inhibitor is an ultra-rare disease characterized by life-threatening recurrent, unpredictable swelling, and...
Copyright 2023-2026 - www.financetom.com All Rights Reserved